Market research for healthcare, pharma & industry

Start from the decision, not the method. If you need to size an opportunity or validate a forecast, lead with quantitative research. If you need to understand why a prescriber hesitates or a committee stalls, lead with qualitative. If the work runs inside a regulated care environment with payer and procurement gates, use a healthcare-specific program. Most launch and access projects end up blending the first two.

BioNixus publishes market research entry points across 31 countries — prioritising the United States, Canada, Europe, Brazil, and MENA, with further coverage across Africa and Asia-Pacific. Seven GCC markets include the full sixteen-industry matrix with company-intent pages and 2026 listicles; global markets link to healthcare hubs, pharmaceutical BOFU pages, and country–industry URLs.

Sixteen industry verticals: MedTech, healthcare providers, biotech, consumer health, FMCG, retail, financial services, telecom, technology, energy, real estate, automotive, hospitality, public sector, education, and media. Each has a global industry hub at /market-research/{industry} plus country-specific entry points worldwide.

Yes — and it is one of the most common briefs we run. A single program office coordinates fieldwork across markets so leadership gets numbers that compare like-for-like, while local modules preserve FDA, HTA, SFDA, and payer nuance that a regional average would flatten.

After a short objective workshop and a feasibility check, focused modules can move to field within one to two weeks. Multi-country programs take longer — ethics approvals and hospital access add real calendar time — and where a specialist sample is genuinely scarce, we tell you up front rather than after the contract is signed.